[Effects of the new brondilatator reproterol on the cardiac function during treatment of bronchial asthma and chronic obstructive bronchitis (author's transl)].
The new beta-adrenergic phenylethy-aminoalkyl-xanthine derivative 7-(3-[2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino]-propyl)-theophylline (reproterol, Bronchospasmin) was tested in two patient groups afflicted with bronchial asthma or chronic obstructive bronchitis. Neither  single i.v. administration nor single and 4-week long-term application of blood pressure or ECG tracings. Dosages of i.v. 60 and 90 mug, single peroral administration of 20 mg or long-term therapy with 60 mg in either 3 or 6 daily doses, definitely and significantly improved disturbances in the pulmonary ventilation (Rt, EGV, FEV1). This new preparation represents a predominantly beta2-mimetic  broncholysis as well as the absence of cardiovascular side effects.
D000284:Administration, Oral; D001794:Blood Pressure / Q000187:drug effects; D001993:Bronchodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010627:Phenethylamines / Q000009:adverse effects* / Q000627:therapeutic use; D014970:Xanthines / Q000009:adverse effects* / Q000627:therapeutic use
D001993:Bronchodilator Agents; D010627:Phenethylamines; D014970:Xanthines
Effekte des neuen Bronchodilatators Reproterol auf die Herzfunktion bei der Therapie von Asthma bronchiale und chronisch obstruktiver Bronchitis